Jazz Pharmaceuticals (JAZZ) Research & Development (2016 - 2025)
Jazz Pharmaceuticals has reported Research & Development over the past 16 years, most recently at $213.9 million for Q4 2025.
- Quarterly results put Research & Development at $213.9 million for Q4 2025, down 11.06% from a year ago — trailing twelve months through Dec 2025 was $842.6 million (down 4.69% YoY), and the annual figure for FY2025 was $782.7 million, down 11.46%.
- Research & Development for Q4 2025 was $213.9 million at Jazz Pharmaceuticals, up from $198.2 million in the prior quarter.
- Over the last five years, Research & Development for JAZZ hit a ceiling of $240.5 million in Q4 2024 and a floor of $76.6 million in Q1 2021.
- Median Research & Development over the past 5 years was $190.0 million (2025), compared with a mean of $180.6 million.
- Biggest five-year swings in Research & Development: surged 79.33% in 2021 and later dropped 14.71% in 2024.
- Jazz Pharmaceuticals' Research & Development stood at $155.4 million in 2021, then grew by 11.01% to $172.6 million in 2022, then increased by 25.53% to $216.6 million in 2023, then rose by 11.03% to $240.5 million in 2024, then dropped by 11.06% to $213.9 million in 2025.
- The last three reported values for Research & Development were $213.9 million (Q4 2025), $198.2 million (Q3 2025), and $190.0 million (Q2 2025) per Business Quant data.